FOLR1 and neoplasm: BLI confirmed that after treatment with FRα CAR T cells, mice bearing MDA-231.FRα tumors had less residual tumor burden, compared to mice with MDA-231 tumor (Fig. 6b, d), despite beginning therapy with greater tumor burden (Fig. 6b, d).